If you have a penchant for ASX growth shares like I do, then it could be worth checking out the three in this article.
That's because they are high-quality picks that have been named as buys by analysts. Here's what you need to know about them:
Image source: Getty Images
Pro Medicus Ltd (ASX: PME)
The first ASX growth share that could be a buy is Pro Medicus. It is the health medical imaging software company behind the Visage platform. This platform is in high demand and used by some of the world's top hospitals and health networks.
Pro Medicus boasts high gross margins and sticky recurring revenue from long-term contracts. And with the company increasingly winning competitive tenders in the U.S., where healthcare systems are digitising rapidly and demanding faster, AI-enhanced diagnostic tools, it appears well-placed for growth over the next decade. Especially given its expansion into other areas, such as cardiology and "other ologies."
Morgan Stanley is a fan of the company and has an outperform rating and $350.00 price target on its shares.
Temple & Webster Group Ltd (ASX: TPW)
Temple & Webster could be another ASX growth share to buy this month.
It is a dominant player in online furniture retail in Australia with an asset-light, high-margin model that benefits from the ongoing shift in consumer behaviour toward e-commerce.
It continues to execute well on growth initiatives and deliver impressive numbers. In fact, this month it reported a 20.7% increase in revenue and a 43.2% jump in EBITDA for FY 2025.
And with the shift to online still only in its early days, Temple & Webster appears well-positioned to continue its growth long into the future.
The team at Citi is bullish on the company's outlook. It has a buy rating and $34.32 price target on its shares.
Xero Ltd (ASX: XRO)
Finally, Xero could be a top ASX growth share to buy. It is a cloud-based accounting platform that has grown from a small startup to a global small business software leader with over 4 million subscribers.
It also appears well-placed for growth over the coming decade. Particularly given how recent acquisitions and product expansions (including payments and AI integration) have widened Xero's economic moat, enabling deeper engagement with existing customers and higher average revenue per user (ARPU). This includes the acquisition of Melio, which positions it perfectly to compete in a global total addressable market estimated to be 100 million.
Macquarie is feeling positive about its long-term outlook and has an outperform rating and $204.00 price target on its shares.
